Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Background Co-inhibition of poly (ADP-ribose) polymerase (PARP) and androgen receptor
activity might result in antitumour efficacy irrespective of alterations in DNA damage repair …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal
disease with current standard-of-care therapies. Homologous recombination repair (HRR) …

Background Preclinical studies and results of a phase 2 trial of abiraterone and olaparib
suggest a combined antitumor effect when the poly (adenosine diphosphate [ADP]-ribose) …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Preclinical evidence has suggested an interplay between the androgen receptor, which
largely drives the growth of prostate cancer cells, and poly (ADP-ribose) polymerase. This …

Background Patients with metastatic castration-resistant prostate cancer and homologous
recombination repair (HRR) mutations have a better response to treatment with the poly …

A mounting body of evidence now indicates that PARP inhibitors have the potential to be
used as a foundation for both monotherapy and combination strategies across a wide …